Xeljanz^® Achieved Rapid Induction of Efficacy

XELJANZ^® (tofacitinib citrate) induction therapy^* achieved rapid^† induction of efficacy^1,2

A significantly greater proportion of patients taking XELJANZ^® (tofacitinib citrate) 10 mg BID achieved treatment end points versus placebo at Week 8 across multiple efficacy parameters^1,2

Pooled Central Read Data From OCTAVE 1 and OCTAVE 2 Induction Studies^1,2

Adapted from Sandborn WJ, et al. 2017.

*Two randomised, multicentre, double-blind, placebo-controlled Phase 3 studies of patients with moderate to severe UC who received XELJANZ^® (tofacitinib citrate) 10 mg BID or placebo for 8 weeks.^1 
†Rapid induction as early as Week 2 in OCTAVE 1 and OCTAVE 2 studies.
^‡Remission was stringently defined as a total Mayo score of ≤2, with no individual subscore of >1 and a rectal bleeding subscore of 0.1. 
^§Improvement of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).
^IIClinical response was defined as a decrease from baseline in the Mayo score of ≥3 points and ≥30%, with an accompanying decrease in the subscore for rectal bleeding of ≥1 point or absolute subscore for rectal bleeding of 0 or 1.¹ The recommended dose is 10 mg given orally BID for induction for 8 weeks.³  The recommended dose for the maintenance treatment is XELJANZ^® (tofacitinib citrate) 5 mg given orally BID.

BID, twice daily; OCTAVE, Operationally Critical Threat, Asset and Vulnerability Evaluation; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis.

References: